Hycor Gets OK for 2nd Autoimmune Kit
- Share via
Hycor Biomedical Inc., a Garden Grove maker of medical diagnostic products, said Tuesday that the U.S. Food and Drug Administration has cleared it to market another autoimmune test kit in the United States.
Hycor said in a press release that the kit, called Rheumatoid Factor IgG ELISA, detects an antibody found in 80% of patients with rheumatoid arthritis. The company said the tests are based on enzyme immunoassay technology and intended to replace older methodologies, including agglutination methods.
Last week, the company said it received FDA clearance to market its anti-cardiolipin kit, which detects the presence of antibodies that can cause clotting problems and low platelet counts in patients with autoimmune disease.
Hycor’s stock closed Tuesday at $2.25 a share, up 19 cents in Nasdaq trading.
Inside the business of entertainment
The Wide Shot brings you news, analysis and insights on everything from streaming wars to production — and what it all means for the future.
You may occasionally receive promotional content from the Los Angeles Times.
